High-dose Vorinostat effective at treating relapsed lymphomas

Results of phase 1 clinical trial lead way to use of new class of drugs to treat aggressive blood cancer

2013-02-04

(Press-News.org) SEATTLE – Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease. Reporting the results of a first-of-its-kind phase 1 clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of Vorinostat (suberoylanilide hydroxamic acid) in combination with another round of commonly used second-line drugs resulted in a 70 percent response rate, including several patients whose lymphoma cells disappeared entirely. According to Ajay Gopal, M.D., associate member of the Fred Hutch Clinical Research Division and corresponding author of the paper, published online in the British Journal of Haematology, the study results open the way to potentially solve the dilemma of how to effectively treat patients when modern cancer drugs fail after the first try. And, he said, it sets the stage for using a new class of drugs called histone-deacetylase inhibitors (HDAC), of which Vorinostat is one, to sensitize tumor cells to the cancer-killing effects of chemotherapy. Patients treated in the trial had several types of lymphoma, however the best responses were seen in those who had Hodgkin and diffuse large B-cell lymphomas, two of the most aggressive types that typically require a stem cell transplant to cure if they are not cured after the first line of treatment. Knocking back the cancer raises the likelihood for a successful transplant. "The better the response, the better the outcome will be when patients proceed to a stem cell transplant designed to cure them of their disease," said Elizabeth Budde, M.D., Ph.D., a research associate in the Fred Hutch Clinical Research Division and first author of the study. The researchers noted that while the current front-line chemotherapy drugs are the most effective yet against lymphomas, patients who relapse after receiving them are less likely to achieve long-term, disease-free survival when current second-line or "salvage" therapies are applied. This is because the cancers develop resistance to the drugs or the tumor's biology changes in some way to reduce their effectiveness. Lymphoma refers to a group of cancers that strike the lymphatic system, which is a key part of the immune system. Lymphomas are broadly classified as either Hodgkin or non-Hodgkin. Some lymphomas are highly curable; others require complex treatment. Preclinical studies at Fred Hutch and other research centers have found Vorinostat to be effective when used along with the standard chemotherapy combo, which is known by the acronym (R)ICE for rituximab, ifosphamide, carboplatin and etoposide. Vorinostat works by blocking signals to tumor-suppressor genes, which allows those genes to induce tumor cell death. Vorinostat is approved by the Food and Drug Administration to treat cutaneous T-cell lymphoma. The standard dose is 400 milligrams per day. It is manufactured by Merck & Co. The phase 1 trial involved 27 patients at about a dozen sites that are members of the Puget Sound Oncology Consortium. Because the drugs can be taken orally, the patients could self-treat at home. A novel two-stage dose escalation schedule developed at Fred Hutch was used to speed the time it took to determine the maximum effective dose of Vorinostat with the fewest side effects, which was 500 milligrams twice a day. Some level of response was observed in 19 patients, including eight complete responses. The most common side effects were gastroenterological, which led researchers to recommend giving future patients preventive medicines while taking Vorinostat. Because many of the patients were destined for an autologous hematopoietic stem cell transplant as the next treatment step, researchers also evaluated the ability to mobilize and collect the patients' peripheral blood stem cells after the drug therapy was administered. They were successful in 20 of 21 patients. Budde said the next step is to conduct a phase 2 study of patients who have diffuse B-cell lymphoma because the drug regimen worked best in these patients and it is the most aggressive of lymphomas. ### The study was funded by several sources, including the National Institutes of Health, Lymphoma Research Foundation, Leukemia and Lymphoma Society, the Mary A. Wright Memorial Research Fund, Washington Life Sciences Discovery Fund, and Merck Sharp & Dohme Corp. Budde and Gopal received funding support from Merck Sharp & Dohme Corp. In addition to Budde and Gopal, study co-authors included researchers at the University of Washington; Massachusetts General Hospital, Valley Medical Center in Renton, Wash.; Great Falls Clinic in Great Falls, Mont.; and Yakima Regional Medical & Cardiac Center in Yakima, Wash. Editor's note: A copy of the paper "A phase 1 study of pulse high-dose Vorinostat (V) plus rituximab (R), ifosphamide, carboplatin and etoposide (ICE) in patients with relapsed lymphoma" can be obtained here or by contacting Dean Forbes in media relations.

About Fred Hutchinson Cancer Research Center

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fhcrc.org or follow Fred Hutch on Facebook, Twitter or YouTube.

CONTACT Dean Forbes END

ELSE PRESS RELEASES FROM THIS DATE:

Shame about past alcoholism predicts relapse and declining health in recovering alcoholics

2013-02-04

Feeling shame about past instances of problem drinking may increase the likelihood of relapse and other health problems, according to a new study in Clinical Psychological Science, a journal of the Association for Psychological Science. The study, conducted by researchers from the University of British Columbia, shows that behavioral displays of shame strongly predicted whether recovering alcoholics would relapse in the future. Public shaming has long been viewed as a way to encourage people to amend their ways and research suggests that experiences of shame can motivate ...

Beef Up: Middle-aged men may need more to maintain muscle mass

2013-02-04

Ottawa, ON (February 4, 2013) – People tend to lose muscle mass as they age; researchers are investigating ways to delay or counteract age-related muscle loss. A study conducted by the Exercise Metabolism Research Group at McMaster University suggests that current guidelines for meat consumption are based on the protein needed to prevent deficiency without consideration for preservation of muscle mass, particularly for older individuals who are looking to maintain their muscle as they age. This research was published in the journal Applied Physiology, Nutrition, and Metabolism. Thirty-five ...

President Obama awards nation's top scientists and innovators highest honor

2013-02-04

President Obama today awarded 12 eminent researchers the National Medal of Science and 11 extraordinary inventors the National Medal of Technology and Innovation, the highest honors bestowed by the U.S. government upon scientists, engineers and inventors. The recipients received their awards at a White House ceremony. This marks the 50th anniversary of the presentation of the first National Medals of Science in 1963 by President John F. Kennedy. "I am proud to honor these inspiring American innovators," Obama said when the awardees were announced. "They represent the ...

Amyloid imaging shows promise for detecting cardiac amyloidosis

2013-02-04

Reston, Va. – While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) with 11C-PIB can positively visualize amyloid deposits in the heart. Currently there is no noninvasive test available for specific diagnosis. Cardiac amyloidosis is a deadly disorder caused by abnormal amyloid deposits in the heart tissue. Early diagnosis before ...

USDA scientists say mix-and-match cover cropping can optimize organic production

2013-02-04

This press release is available in Spanish. Farmers can fine-tune their use of cover crops to help manage costs and maximize benefits in commercial organic production systems, according to U.S. Department of Agriculture (USDA) scientists. Production expenses for high-value organic crops like lettuce and broccoli can exceed $7,000 per acre, so producers often try to streamline costs with an annual two- to three-crop rotation. Agricultural Research Service (ARS) horticulturalist Eric Brennan designed a long-term investigation that examined several different cover ...

Little House books' Mary Ingalls probably did not go blind from scarlet fever, U-M study says

2013-02-04

Ann Arbor, Mich. — In the beloved American stories of the Little House on the Prairie, author Laura Ingalls Wilder writes emotionally about how scarlet fever robs her big sister Mary of her sight. But in a new study published today in the journal Pediatrics, University of Michigan researchers found it is likely scarlet fever had nothing to do with Mary's blindness. Senior author Beth A. Tarini, M.D., and her co-authors used evidence from newspaper reports, Laura Ingalls' memories and school registries to conclude Mary's blindness was probably caused by viral meningoencephalitis. "Since ...

Can cancer be turned against itself?

2013-02-04

Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells. Now Prof. Yoel Kloog of Tel Aviv University's Department of Neurobiology, along with Dr. Itamar Goldstein of TAU's Sackler Faculty of Medicine and the Sheba Medical Center and their students Helly Vernitsky and ...

Study finds incentive price for reducing HIV risk in Mexico

2013-02-04

PROVIDENCE, R.I. [Brown University] — Studies have found that conditional cash transfer programs, in which governments pay citizens if they consistently practice societally beneficial behaviors, have improved pediatric health care and education in Mexico, increased HIV testing in Malawi, and reduced sexually transmitted infections in Tanzania. Public health researchers therefore investigated whether the idea could be applied to HIV risk behaviors among gay men and male sex workers in Mexico City. A new study reports not only that some members of those populations would ...

New kind of extinct flying reptile discovered by scientists

2013-02-04

A new kind of pterosaur, a flying reptile from the time of the dinosaurs, has been identified by scientists from the Transylvanian Museum Society in Romania, the University of Southampton in the UK and the Museau Nacional in Rio de Janiero, Brazil. The fossilised bones come from the Late Cretaceous rocks of Sebeş-Glod in the Transylvanian Basin, Romania, which are approximately 68 million years old. The Transylvanian Basin is world-famous for its many Late Cretaceous fossils, including dinosaurs of many kinds, as well as fossilised mammals, turtles, lizards and ancient ...

In combat vets and others, high rate of vision problems after traumatic brain injury

2013-02-04

Philadelphia, Pa. (February 4, 2013) - Visual symptoms and abnormalities occur at high rates in people with traumatic brain injury (TBI)—including Iraq and Afghanistan War veterans with blast-related TBI, reports a study, "Abnormal Fixation in Individuals with AMD when Viewing an Image of a Face", in the February issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. Vision problems are similar for military and civilian patients with TBI, ...

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

High-dose Vorinostat effective at treating relapsed lymphomas

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: